T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals

World Journal of Gastroenterology

Volumn 14, Issue 16, 2008, Pages 2529-2533

  Weihrauch, Martin R ^a   von Bergwelt Baildon, Michael ^a   Kandic, Milos ^a   Wescott, Martin ^b   Klamp, Winfried ^a   Rösler, Joachim ^a   Schultze, Joachim L ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Wuppertaler Stadtwerke AG   (Germany)

Author keywords

Hepatitis B; Non responder; T cell; Vaccination

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 4;

ADULT; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; VACCINATION;

EID: 47849125310     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2529     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Available from: URL: http://www.cdc.gov/.2002
2. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 Suppl 1: S47-S49
3. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204
4. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859
5. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Syndman DR, Platt R, Crumpacker CS. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986; 105: 356-360
6. Dienstag JL, Werner BG, Polk BF, Snydman DR, Craven DE, Platt R, Crumpacker CS, Ouellet-Hellstrom R, Grady GF. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984; 101: 34-40
7. Katkov WN, Dienstag JL. Prevention and therapy of viral hepatitis. Semin Liver Dis 1991; 11: 165-174
8. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321: 708-712
9. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51: 593-604
10. Hohler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, Starke R, Zepp F, Sanger R, Clemens R, Meyer zum Buschenfelde KH, Rittner C. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998; 59: 212-218
11. Hohler T, Stradmann-Bellinghausen B, Starke R, Sanger R, Victor A, Rittner C, Schneider PM. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002; 37: 387-392
12. Lango-Warensjo A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998; 52: 374-380
13. Docci D, Cipolloni PA, Mengozzi S, Baldrati L, Capponcini C, Feletti C. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up. Nephron 1992; 61: 352-353
14. Bruguera M, Cremades M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med 1989; 87: 30S-32S
15. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87: 36S-40S
16. Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G, Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 1994; 39: 163-168
17. Kardar GA, Jeddi-Tehrani M, Shokri F. Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 2002; 55: 311-314
18. Jarrosson L, Kolopp-Sarda MN, Aguilar P, Bene MC, Lepori ML, Vignaud MC, Faure GC, Kohler C. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 2004; 22: 3789-3796
19. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995; 154: 520-529
20. Desombere I, Cao T, Gijbels Y, Leroux-Roels G. Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation. Clin Exp Immunol 2005; 140: 126-137
21. Chiou SS, Yamauchi K, Nakanishi T, Obata H. Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology 1988; 64: 545-550
22. Watanabe H, Okumura M, Hirayama K, Sasazuki T. HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells. Tissue Antigens 1990; 36: 69-74
23. Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, Alper CA, Yunis EJ. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol 1997; 58: 42-51
24. Salazar M, Deulofeut H, Granja C, Deulofeut R, Yunis DE, Marcus-Bagley D, Awdeh Z, Alper CA, Yunis EJ. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics 1995; 41: 366-374
25. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, DeVera A, Chen GT, Kellner A. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307: 1481-1486
26. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841
27. Bauer T, Jilg W, Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-577
28. Bocher WO, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld KH, Lohr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or alter HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999; 29: 238-244
29. Sylvan SP, Hellstrom UB. HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro. Immunology 1990; 70: 197-202
30. Tsutsui H, Mizoguchi Y, Morisawa S. There is no correlation between function and lymphokine production of HBs-antigen-specific human CD4(+)-cloned T cells. Scand J Immunol 1991; 34: 433-444
31. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988; 260: 1734-1738
32. Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31: 521-527
33. Wistrom J, Settergren B, Gustafsson A, Juto P, Norrby RS. Intradermal vs intramuscular hepatitis B vaccinations. JAMA 1990; 264: 181-182
34. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine 1997; 15: 1618-1623
35. Ambrosch F, Wiedermann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N, Thiriart C, Slaoui M, Thoelen S. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000; 18: 2095-2101
36. Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, Vandepapeliere P, Slaoui M, Meheus A. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16: 708-714
37. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701